Bionano reiterates $26M–$30M 2025 revenue guidance as core consumables and software sales grow 15% year over year

Earnings Call Insights: Bionano Genomics (BNGO) Q3 2025

MANAGEMENT VIEW

* CEO Robert Holmlin highlighted a strategic focus on "transforming pathology...from pathology's analog past to a digital future." He explained that Bionano's shift is "away from one based in aggressively growing the installed base toward a model that's driving utilization of our solutions within a subset of our existing OGM and VIA software user base." Holmlin described these as "routine users" who can "generate significant consumables and software revenues and will drive most of our revenue growth in the near-term."
* Holmlin outlined four strategic pillars: supporting routine users, driving software adoption, building reimbursement support, and improving profitability. He stated, "We believe our performance in the third quarter and year-to-date validates that focusing on these routine users is restoring growth in our core business."
* The company reported "total revenue for the third quarter of 2025 was $7.4 million, reflecting an increase of 21% compared to the third quarter of 2024." Core revenues increased by 12% year-over-year after accounting for a $0.5 million write-down.
* Consumables and software sales grew 15% year-over-year in Q3, with these categories representing 72% of the product mix.
* Non-GAAP gross margin reached 46%, up from 26% a year earlier. Non-GAAP operating expense was $9.7 million, a 40% year-over-year reduction.
* The installed base grew to 384 systems, with 7 new installations and 1 return for a net increase of 3. Year-to-date, 23 new systems were installed.
* Bionano ended the quarter with $31.8 million in cash, cash equivalents, and available-for-sale securities, with $10.3 million subject to restrictions. A $10 million public offering in September extended the cash runway into Q3 2026.
* Holmlin commented, "We are reiterating our full year 2025 revenue guidance of $26 million to $30 million. We expect the fourth quarter of 2025 revenues to be in the range of $7.5 million to $7.9 million."

OUTLOOK

* Holmlin reiterated, "We are reiterating our full year 2025 revenue guidance of $26 million to $30 million. We expect the fourth quarter of 2025 revenues to be in the range of $7.5 million to $7.9 million."
* The company expects to "exceed the prior range of 20 to 25 systems" for new OGM installations in 2025, "likely surpassing the high end of that."
* No updated EPS guidance or comparison to analysts' estimates was provided.

FINANCIAL RESULTS

* The company reported "total revenue for the third quarter of 2025 was $7.4 million."
* Consumables and software sales grew 15% year-over-year in Q3.
* Bionano sold a record 8,390 flow cells in Q3, a 7% increase over the prior year, with existing customers' purchases up 6% year-over-year.
* Non-GAAP gross margin was 46%. Non-GAAP operating expense was $9.7 million, a 40% reduction compared to Q3 2024.
* Cash, cash equivalents, and available-for-sale securities totaled $31.8 million, including $10.3 million under restrictions.
* The installed base reached 384 systems, with 23 new installations year-to-date.

Q&A

* Yi Chen, H.C. Wainwright: Asked about the "potential peak level of utilization for these routine use customers" and the expected timeline. Holmlin responded, "the average utilization across these routine users...is about 4 samples per week. But at the highest end of the spectrum, it's as high as 40 samples per week...a reasonable target for us to shoot for is maybe the midpoint between the 4 and the 40, so getting up to in the low-20s on average across all of the routine users."
* Yi Chen, H.C. Wainwright: Inquired about the Japanese market. Holmlin said, "we have really only 1 system installed in Japan...the interest in Japan has evolved...there's tremendous potential in Japan," noting the market could develop similarly to the U.S. with time and local data.
* Yi Chen, H.C. Wainwright: Asked about operating expenses stability. Holmlin answered, "Yes. I think this is the range that we're intending to be in...our overall intention is to keep things as flat as we possibly can, except where opportunities justify it."

SENTIMENT ANALYSIS

* Analyst tone was inquisitive but constructive, focusing on utilization potential, international growth, and expense discipline.
* Management maintained a confident and consistent tone, stating, "We believe our performance...validates that focusing on these routine users is restoring growth in our core business," and "We are reiterating our full year 2025 revenue guidance."
* Compared to the previous quarter, analyst sentiment remained neutral to slightly positive, while management sustained its confident tone, emphasizing progress and discipline in strategy execution.

QUARTER-OVER-QUARTER COMPARISON

* Revenue grew from $6.7 million in Q2 to $7.4 million in Q3.
* Consumables and software sales growth in Q3 was 15% year-over-year, compared to 16% in Q2.
* Gross margin in Q3 was 46%, lower than Q2's 52%, but both quarters highlighted margin improvements versus prior years.
* Operating expenses in Q3 decreased to $9.7 million from $8.8 million in Q2, maintaining a significant year-over-year reduction.
* Installed base grew to 384, with 23 new installations year-to-date, up from 378 at the end of Q2 and 16 new systems through the first half of the year.
* Management reiterated the same full-year revenue guidance and increased expectations for system installations.
* Analyst questions shifted from software adoption and instrument return rates to utilization ramp and international expansion.
* Management's confidence in the core strategy and financial discipline was consistent with the prior quarter, with continued focus on routine user growth and margin expansion.

RISKS AND CONCERNS

* Management acknowledged the need for ongoing support to drive utilization among routine users and emphasized the importance of expanding menu applications at customer labs.
* The company noted that international market development, such as in Japan, is gradual and requires building local data.
* There were no new specific risks cited regarding revenue or expenses, but management highlighted monitoring operating expenses and investing only where justified.

FINAL TAKEAWAY

Bionano Genomics emphasized its continuing shift to driving utilization within its existing routine user base, resulting in record flow cell sales, strong year-over-year growth in consumables and software, and improved gross margins. The company reiterated its 2025 revenue guidance of $26 million to $30 million, expects to surpass prior system installation targets, and remains focused on cost discipline. Management signaled confidence in the business model, citing the positive impact of the strategy and ongoing international expansion efforts, while maintaining a cautious approach to operating expenses and future investments.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/bngo/earnings/transcripts]

MORE ON BIONANO GENOMICS

* Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4843569-bionano-genomics-inc-bngo-q3-2025-earnings-call-transcript]
* Bionano Genomics, Inc. (BNGO) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript [https://seekingalpha.com/article/4826078-bionano-genomics-inc-bngo-presents-at-h-c-wainwright-27th-annual-global-investment-conference]
* Bionano jumps 6% on Q3 revenue beat, 2025 guidance range [https://seekingalpha.com/news/4521988-bionano-jumps-6-q3-revenue-beat-2025-guidance-range]
* Bionano Genomics reports Q3 results [https://seekingalpha.com/news/4521820-bionano-genomics-reports-q3-results]
* Seeking Alpha’s Quant Rating on Bionano Genomics [https://seekingalpha.com/symbol/BNGO/ratings/quant-ratings]